Zai Lab Ltd (ZLAB): יחס שווי שוק להכנסות

Zai Lab Limited (ZLAB) builds its defensive moat through exclusive licenses for Western biologics and deep regulatory expertise. The production cycle relies on a combination of proprietary plants in Suzhou and contract manufacturing capacities. Revenue is generated by introducing innovative drugs to the Chinese market. The current price-to-sales ratio on this chart illustrates the valuation trend, where 6.60 represents the current level of the metric.

Optimizing drug distribution in Asia directly impacts the revenue of Zai Lab Limited (ZLAB), which serves as the denominator in the P/S ratio calculation. This metric compares the business's market value with its actual sales volumes, allowing the price-to-sales multiple history to determine whether the low share price results from a fundamental decline in commercial activity and the risk of capital freezing.